Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus and, more recently, for weight management in adults with obesity or overweight with weight-related comorbidities (as per MHRA/EMC SmPC for Mounjaro)
Its ability to work throughout the body makes it especially useful for individuals dealing with multiple areas of strain or injury
However, individual responses vary widely based on baseline health and medication interactions
Over 12 months: approximately 1% to 6% of participants across the two cohorts newly met criteria for addiction, as assessed with two validated interview-based measures of moderate-to-severe opioid use disorder based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria, and approximately 9% and 22% of participants across the two cohorts newly met criteria for prescription opioid abuse and misuse [defined in DRUG ABUSE AND DEPENDENCE], respectively, as measured with a validated self-reported instrument
During your consultation, our team will go over any allergies, previous surgeries, current medications, and lifestyle factors to evaluate your candidacy for weight loss injections like Semaglutide or Tirzepatide
